About the Company
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for debilitating skin diseases with a focus on its lead asset sofpironium bromide for the treatment of hyperhidrosis. Brickell's executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell's strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative and differentiated pharmaceutical products that Brickell believes can be successful in the marketplace and transform lives by solving currently unmet patient needs.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $BBI News
Coinbase Cost Cuts, Netflix Earnings And Factor Investing: Forbes AI Newsletter - July 23rd
The company’s EPS numbers have grown by 8.43% over the past 12 months. Brickell Biotech Inc (BBI) – The pharmaceutical company is a Top Short for next week with our AI rating them an F in our ...
Monica E. Luchi's Net Worth
Who is Monica E. Luchi? Monica E. Luchi does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include ...
Krystal Biotech moves to next step in clinical trial
Krystal Biotech has announced the first patient has joined a trial for its inhaled treatment for a solid lung cancer tumor.
Fortress Biotech, Inc. (FBIO)
Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...
Oncolytics Biotech Inc. (ONCY)
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, is pleased to announce the submission of a Type C meeting ...
Noile-Immune Biotech Inc
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
KRYS Krystal Biotech, Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes ...
Susan Brickell
Susan Brickell is a senior e-commerce editor at Meredith, covering products in the form of reviews, roundups, and gift guides. She's been a market editor and writer for nearly a decade with her ...
FBIO Fortress Biotech, Inc.
Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as ...
Oncolytics Biotech Inc.
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of ...
Oncolytics Biotech Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Fortress Biotech Inc FBIO
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Loading the latest forecasts...